Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV NEPA for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients
NCT06904235Phase 2Recruiting
- Sponsor
- Helsinn
- Start
- Jul 2025
- Primary completion
- Oct 2027
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of fosnetupitant and palonosetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Helsinn. Primary endpoints: Netupitant exposure parameter at 168 hours, Netupitant exposure at 168 hours and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
fosnetupitantpalonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT06904235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06904235.